Not known Facts About Imipenem
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge multiple intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial aims were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis